Lepu Medical Technology 乐普医疗
9 significant filings since 31 May 2026: 4 on pledge released, 2 on dividend and 1 on major holder buying, and 2 other kinds. The latest, on 24 Aug 2026: 关于实际控制人、董事长增持本公司股份的公告.
自 31 May 2026 起有 9 份重大公告：pledge released 4 份、dividend 2 份、major holder buying 1 份，另有 2 类。最新一份（24 Aug 2026）：关于实际控制人、董事长增持本公司股份的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 7 Jan 2026 | 国金证券 | 杨欣,赵中平,杨雨钦 | Buy 买入 | ▼ | Outperform 增持 |
| 10 Oct 2022 | 国金证券 | 袁维 | Outperform 增持 | ▲ | Buy 买入 |
| 29 Apr 2019 | 东兴证券 | 杨若木 | Buy 买入 | ▼ | Outperform 增持 |
| 3 Mar 2019 | 长城国瑞证券 | 黄文忠,霍亮 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 国金证券 | 杨欣,杨雨钦,赵中平 | Outperform 增持 | 23 Apr 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 2 reports. 每行为该券商近十二个月的最新研报；2 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。